Back to top

messenger-rna: Archive

Zacks Equity Research

Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change